Heron Therapeutics (HRTX) Enterprise Value (2011 - 2026)

Heron Therapeutics (HRTX) has reported Enterprise Value for 16 consecutive years, with $39.0 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Enterprise Value fell 85.91% year-over-year to $39.0 million; the trailing twelve-month figure through Jun 2026 stood at $39.0 million (down 85.91% YoY), and the FY2025 full-year result was $198.2 million, up 14.24% from the prior year.
• Enterprise Value retreated to $39.0 million in Q2 2026 per HRTX's latest filing, from $106.6 million in the prior quarter.
• Across five years, Enterprise Value topped out at $474.3 million in Q1 2022 and bottomed at $39.0 million in Q2 2026.
• Historically, Enterprise Value has averaged $226.0 million across 5 years, with a median of $200.5 million in 2022.
• The sharpest annual moves came in 2024 and 2026: Enterprise Value surged 256.43% in 2024, then sank 85.91% in 2026.
• Over 5 years, Enterprise Value stood at $213.0 million in 2022, then retreated by 17.82% to $175.1 million in 2023, then declined by 0.92% to $173.5 million in 2024, then advanced by 14.24% to $198.2 million in 2025, then sank by 80.33% to $39.0 million in 2026.
• According to Business Quant data, Enterprise Value over the past three periods registered $39.0 million, $106.6 million, and $198.2 million for Q2 2026, Q1 2026, and Q4 2025 respectively.